CD133-AREG Melanoma Proliferation Research Program
preclinicalresearch program · medium
Characterize CD133-driven melanoma cell proliferation and identify therapeutic targets linked to amphiregulin and EGFR/MAPK signaling.
Doxycycline-inducible CD133 melanoma cell lines, RNA-seq, qRT-PCR, immunoblotting, cell growth assays, EGFR inhibition, and AREG siRNA knockdown.
2024 Cells publication identified amphiregulin as a mediator of CD133-induced melanoma proliferation.
CD133 induction increased cell growth and activated EGFR/MAPK signaling; gefitinib and AREG knockdown reversed CD133-driven growth effects.
CometChip DNA Damage Assessment in Non-Model Species
exploratoryresearch program · medium
Evaluate whether high-throughput CometChip can measure DNA damage responses across non-model species relevant to aging, stress resistance, and cancer biology.
CometChip assay applied to UVA-induced DNA damage in fibroblasts from turtle and mammalian species.
2025 BMC Research Notes publication assessed CometChip feasibility across turtles and mammals.
The assay detected DNA damage across species; turtles showed lower UVA-induced DNA damage than mammals, but endogenous variation and cell-culture differences limited standardization.
DNA Damage Quantification Platform
undisclosedplatform · high
Quantify DNA damage in cells and provide insight into therapeutics for aging disorders associated with DNA damage accumulation.
Cellular DNA damage measurement technology; specific assay details are not disclosed in the supplied company description.
Company website describes Amelia Technologies as developing DNA damage quantification technologies for aging-disorder therapeutics insight.
NRAS-Mutant Melanoma MEK/AKT Combination Program
preclinicaldrug program · medium
Develop more effective combination approaches for high-risk NRAS-mutant melanoma stem cells by targeting MAPK and AKT survival pathways.
Combination treatment with MEK inhibitor trametinib and pan-AKT inhibitor capivasertib in patient-derived melanoma cells and mouse xenograft studies.
2025 Cells publication reported in vitro and in vivo preclinical results for trametinib plus capivasertib.
Combination treatment reduced cell survival, apoptosis resistance, colony formation, and xenograft tumor growth effects associated with CD133 expression.
Skin Immuno-CometChip Topical Genotoxicity Screening
exploratorybiomarker · medium
Detect DNA damage caused by topical genotoxic agents in epidermal stem and basal cells using skin-relevant models.
High-throughput Immuno-CometChip assay in 2D epidermal cells and 3D skin equivalents exposed topically to DNA-damaging agents.
Publication reported design and testing of the Skin Immuno-CometChip assay in 2D and 3D skin culture systems.
The supplied abstract states the assay was designed to detect agents that create DNA damage in epidermal stem and basal cells and was tested against known DNA-damaging agents.
UVA Nail Dryer Skin Cell Genotoxicity Study
exploratoryresearch program · medium
Investigate how UVA-emitting nail dryers can cause cytotoxic and genotoxic effects in human skin cells after low UVA exposure.
Human skin-cell exposure studies measuring UVA fluence, temperature changes, cytotoxicity, genotoxicity, and DNA damage.
2024 International Journal of Toxicology publication reported the role of temperature in UVA nail dryer toxicity.
Prolonged exposure induced significant DNA damage; elevated device temperature acted synergistically with UVA to increase cytotoxic and genotoxic impact.
